FeesSafety
Pluang+

Rentokil Initial boosts profits and shareholder returns post-Terminix acquisition with digital growth and cost focus.

Market News
24 Oct 2026
Seeking Alpha
View Source
Bullish
Rentokil Initial boosts profits and shareholder returns post-Terminix acquisition with digital growth and cost focus.

Rentokil Initial is recovering well after acquiring Terminix, improving key performance indicators and profitability despite earlier integration challenges. The company is focusing on its core pest control and hygiene services, especially in North America, which now accounts for over 60% of revenue. Its valuation is low at 14.4 times forward earnings, with a dividend yield near 3% and a new £200 million share buyback pushing total shareholder returns above 6%. Digital tools like PestConnect and AI adoption are expected to drive further growth and efficiency improvements.

Regarding Rentokil's KPIs heading in the right direction, here is Pluang's Industrials sector market snapshot as of Oct 24, 2026 16:41 WIB: Of 135 priced US Industrials stocks, 52 rose and 81 fell. Notable movers include QXO Inc. at USD 10.51 with a 1-day change of -4.63%, SMX Security Matters plc at USD 1.75 with a 1-day change of -4.37% and a Pluang order activity of 98% Sell / 2% Buy, and Nordic American Tankers Limited at USD 7.86 with a 1-day change of +4.24% and 100% Buy order activity. The most notable figure is the 100% Buy order activity for Nordic American Tankers Limited.

More News

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
44 minutes ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
44 minutes ago
AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker launches guide for Business Class flights from the US to 15 global destinations.

AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...

Others
Neutral
2 hours ago
Ethereum co-founder predicts AI and crypto will merge to enable trusted automated work on blockchain.

Ethereum co-founder predicts AI and crypto will merge to enable trusted automated work on blockchain.

Joseph Lubin, co-founder of Ethereum, predicts that artificial intelligence (AI) and cryptocurrency will merge on the Ethereum blockchain to create a system where automated tasks are commissioned, completed, and paid for with trust guaranteed by bloc...

Protocol Fundamentals
Bullish
4 hours ago
Bitcoin dips near $80K amid lower trading volume and rising exchange reserves, signaling cautious market sentiment.

Bitcoin dips near $80K amid lower trading volume and rising exchange reserves, signaling cautious market sentiment.

Bitcoin's price dropped to around $80,494, down 1.26%, alongside a 14.11% decline in trading volume, indicating weaker market participation. Despite increased network activity and a slight rise in Bitcoin's market dominance, sentiment remained neutra...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App